HER2-low expression in patients with hormone receptor positive and HER2 negative advanced breast cancer treated with ribociclib or palbociclib in combination with endocrine therapy

Basit Öğe Kaydı
dc.contributor.authorKahraman, Seda
dc.contributor.authorHizal, Mutlu
dc.contributor.authorGumusay, Ozge
dc.contributor.authorBasaran, Gul
dc.contributor.authorSeyyar, Mustafa
dc.contributor.authorSahin, Elif
dc.contributor.authorCabuk, Devrim
dc.date.accessioned2026-02-03T11:50:30Z
dc.date.available2026-02-03T11:50:30Z
dc.date.issued2025
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractAim: Hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative breast cancer which represents the most common subgroup of metastatic breast cancer (MBC). Recently, further subclassification for HER2-negative tumors has emerged as HER2-low. There is limited knowledge regarding the effect of HER2-low expression on outcomes of patients with HR-positive and HER2-negative MBC treated with CDK 4/6 inhibitors plus hormonal therapy. Therefore, we evaluated survival parameters according to HER2-low status for this patient group in this study. Material and Methods: As the Turkish Oncology Group (TOG) Project, retrospectively collected data from 423 patients with HR-positive/HER2-negative MBC treated with ribociclib and palbociclib plus letrozole therapy was assessed. Included patients had metastatic first-line therapy and endocrine-sensitive disease. Survival outcomes were compared between HER2-negative and HER2-low patient groups. Conclusion: HER2-low status had no statistically significant impact on survival in patients treated with palbociclib or ribociclib plus letrozole.
dc.identifier.doi10.18663/tjcl.1639022
dc.identifier.endpage262
dc.identifier.issn2149-8296
dc.identifier.issue2
dc.identifier.startpage255
dc.identifier.trdizinid1324161
dc.identifier.urihttps://doi.org/10.18663/tjcl.1639022
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/1324161
dc.identifier.urihttps://hdl.handle.net/20.500.12428/34164
dc.identifier.volume16
dc.indekslendigikaynakTR-Dizin
dc.language.isoen
dc.relation.ispartofTurkish Journal of Clinics and Laboratory
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_TR_20260130
dc.subjectPalbociclib
dc.subjectCyclin-dependent kinase 4/6 inhibitors
dc.subjectHER2-low
dc.subjectribociclib
dc.subjecthormone receptor positive and HER2 negative advanced breast cancer
dc.titleHER2-low expression in patients with hormone receptor positive and HER2 negative advanced breast cancer treated with ribociclib or palbociclib in combination with endocrine therapy
dc.typeArticle

Dosyalar

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu